We have just started an exciting journey to give European patients a bigger and more influential voice in their own individual health care decisions and treatments. We will do so by providing patients with digital tools which will allow them to measure their symptoms in a standardized manner, communicate with their physicians and other healthcare providers and align on the right course of action.
In addition to empowering patients, the H2O project is designed to enable a value-based approach in healthcare systems, improving their sustainability by helping them optimize care delivery and the use of their resources around outcomes that matter to patients. The project will set up independent organisations – the observatories – in four European countries (Austria, Germany, the Netherlands and Spain), initially focused on diabetes, inflammatory bowel disease and oncology. These will provide integrated information on patient outcomes for patients and their healthcare providers for use in clinical care. H2O aims to eventually launch observatories throughout Europe, covering many more disease categories.
For more information, please contact us on:
info@imi-h2o.eu
About the H2O Consortium
We are over 20 public and private partners representing patient groups, leading academic hospitals, and industry who have come together in the H2O partnership. The project is being led by the Medical University of Vienna and the pharmaceutical company Takeda.
H2O is funded by the Innovative Medicines Initiative (IMI), the world’s biggest public-private partnership in life sciences, backed by the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
H2O Partners
| Medizinische Universität Wien | AT |
| Charité - Universitätsmedizin Berlin | DE |
| Erasmus University Medical Center | NL |
| Institut Català de la Salut - Hospital Universitari Vall d’Hebron | ES |
| King’s College Hospital | UK |
| Katholieke Universiteit Leuven | BE |
| European Patients' Forum | BE |
| The European Institute for Innovation through health data | BE |
| The Hyve | NL |
| Teamit Research | ES |
| Karolinska University Hospital | SE |
| Vita-Salute San Raffaele University | IT |
| Netherlands Comprehensive Cancer Organisation | NL |
| Takeda Pharmaceuticales International AG | CH |
| Novartis Pharma AG | CH |
| Abbvie INC | US |
| Eli Lilly and Company Limited | UK |
| Medtronic International Trading SARL | CH |
| Pfizer Limited | UK |
| F. Hoffmann-La Roche Ltd | CH |
| Sanofi-Aventis Recherche & Developpement | FR |
| JDRF International (AP) | US |
| Trial Nation (AP) | DK |
funding
ACKNOWLEDGEMENT
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF.
About IMI
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/
DISCLAIMER
Welcome to H2O website. The H2O Consortium makes no warranties or representations of any kind as to the content’s accuracy, currency or completeness, neither the Consortium, IMI, the European Union, EFPIA nor any party involved in creating, producing or delivering this website shall be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of or inability to use this web site, or any errors or omissions in the content thereof. We strive to maintain all the information as timely and accurate as possible. Should you find incorrect or incomplete data on this website, please inform the webmaster, who will update the information as promptly as possible.
